SDZ 64-412

structure given in first source; PAF antagonist

Also Known As:

5-(4'-(3,4,5-trimethoxyphenylethyl)phenyl)-2,3-dihydroimidazo(2,1-a)isoquinoline; SDZ-64-412; Imidazo(2,1-a)isoquinoline, 2,3-dihydro-5-(4-(2-(3,4,5-trimethoxyphenyl)ethyl)phenyl)-, monohydrochloride

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Isoquinolines: 34
      - SDZ 64-412: 1

Related Diseases

1.	Respiratory Hypersensitivity 05/15/1990 - "SDZ 64-412 pretreatment abolished the airway hyperresponsiveness resulting from repeated Ag challenge. " 05/15/1990 - "The role of platelet-activating factor (PAF) in Ag-induced airway hyperresponsiveness was evaluated in a guinea pig model using the PAF antagonist SDZ 64-412. "
2.	Hypoxia (Hypoxemia) 05/15/1990 - "Each OVA challenge produced significant hypoxia that was unaffected by oral pretreatment with 20 mg/kg SDZ 64-412, 2 h before each challenge (pO2 = 35 +/- 2 mm Hg for OVA alone vs 40 +/- 6 mm Hg for SDZ and OVA groups, respectively). "

Related Drugs and Biologics

1.	Platelet Activating Factor